Relaxin elicits renoprotective actions accompanied by increasing bile acid levels in streptozotocin-induced diabetic mice

• Published in: Biomedicine & pharmacotherapy Vol. 162; p. 114578
• Main Authors: Leo, Chen Huei, Ou, Jamie Li Min, Ong, Eng Shi, Qin, Cheng Xue, Ritchie, Rebecca H., Parry, Laura J., Ng, Hooi Hooi
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.06.2023; Elsevier
• Subjects: Animals; Bile acid; Diabetes Mellitus, Experimental - drug therapy; Diabetic kidney disease; Diabetic Nephropathies - drug therapy; Fibrosis; Inflammation; Inflammation - drug therapy; Kidney; Male; Mice; Oxidative Stress; Relaxin; Relaxin - pharmacology; Streptozocin - pharmacology; NO; Oxidative stress; Inflammation; RXFP1; Relaxin; Bile acid; ROS; Fibrosis; STZ; TGF-β; qPCR; DKD; Diabetic kidney disease
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.114578

The peptide hormone relaxin has potent anti-fibrotic and anti-inflammatory properties in various organs, including the kidneys. However, the protective effects of relaxin in the context of diabetic kidney complications remain controversial. Here, we aimed to evaluate the effects of relaxin treatment on key markers of kidney fibrosis, oxidative stress, and inflammation and their subsequent impact on bile acid metabolism in the streptozotocin-induced diabetes mouse model. Male mice were randomly allocated to placebo-treated control, placebo-treated diabetes or relaxin-treated diabetes groups (0.5 mg/kg/d, final 2 weeks of diabetes). After 12 weeks of diabetes or sham, the kidney cortex was harvested for metabolomic and gene expression analyses. Diabetic mice exhibited significant hyperglycaemia and increased circulating levels of creatine, hypoxanthine and trimethylamine N-oxide in the plasma. This was accompanied by increased expression of key markers of oxidative stress (Txnip), inflammation (Ccl2 and Il6) and fibrosis (Col1a1, Mmp2 and Fn1) in the diabetic kidney cortex. Relaxin treatment for the final 2 weeks of diabetes significantly reduced these key markers of renal fibrosis, inflammation, and oxidative stress in diabetic mice. Furthermore, relaxin treatment significantly increased the levels of bile acid metabolites, deoxycholic acid and sodium glycodeoxycholic acid, which may in part contribute to the renoprotective action of relaxin in diabetes. In summary, this study shows the therapeutic potential of relaxin and that it may be used as an adjunctive treatment for diabetic kidney complications.